Institute of Biomedical Research of Barcelona, Spanish National Research Council, Barcelona, Spain; CiberEHD, Spain; University of Barcelona, Barcelona, Spain; IDIBAPS, Barcelona, Spain.
Institute of Biomedical Research of Barcelona, Spanish National Research Council, Barcelona, Spain; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Mol Metab. 2024 Sep;87:101989. doi: 10.1016/j.molmet.2024.101989. Epub 2024 Jul 15.
Fibrosis contributes to 45% of deaths in industrialized nations and is characterized by an abnormal accumulation of extracellular matrix (ECM). There are no specific anti-fibrotic treatments for liver fibrosis, and previous unsuccessful attempts at drug development have focused on preventing ECM deposition. Because liver fibrosis is largely acknowledged to be reversible, regulating fibrosis resolution could offer novel therapeutical options. However, little is known about the mechanisms controlling ECM remodeling during resolution. Changes in proteolytic activity are essential for ECM homeostasis and macrophages are an important source of proteases. Herein, in this study we evaluate the role of macrophage-derived cathepsin D (CtsD) during liver fibrosis.
CtsD expression and associated pathways were characterized in single-cell RNA sequencing and transcriptomic datasets in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD and hepatocyte-CtsD knock-out mice.
Analysis of single-cell RNA sequencing datasets demonstrated CtsD was expressed in macrophages and hepatocytes in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD (CtsD) and hepatocyte-CtsD knock-out mice. CtsD deletion in macrophages, but not in hepatocytes, resulted in enhanced liver fibrosis. Both inflammatory and matrisome proteomic signatures were enriched in fibrotic CtsD livers. Besides, CtsD liver macrophages displayed functional, phenotypical and secretomic changes, which resulted in a degradomic phenotypical shift, responsible for the defective proteolytic processing of collagen I in vitro and impaired collagen remodeling during fibrosis resolution in vivo. Finally, CtsD-expressing mononuclear phagocytes of cirrhotic human livers were enriched in lysosomal and ECM degradative signaling pathways.
Our work describes for the first-time CtsD-driven lysosomal activity as a central hub for restorative macrophage function during fibrosis resolution and opens new avenues to explore their degradome landscape to inform drug development.
纤维化导致工业化国家 45%的死亡,其特征是细胞外基质(ECM)的异常积累。目前尚无针对肝纤维化的特异性抗纤维化治疗方法,以前药物开发的失败尝试主要集中在阻止 ECM 沉积上。由于肝纤维化在很大程度上被认为是可逆的,因此调节纤维化消退可能提供新的治疗选择。然而,人们对控制纤维化消退过程中 ECM 重塑的机制知之甚少。蛋白水解活性的变化对于 ECM 动态平衡至关重要,巨噬细胞是蛋白酶的重要来源。在此,我们评估了巨噬细胞来源的组织蛋白酶 D(CtsD)在肝纤维化中的作用。
在人类肝硬化的单细胞 RNA 测序和转录组学数据集中,对 CtsD 的表达及其相关途径进行了表征。在新型髓样 CtsD 和肝细胞 CtsD 敲除小鼠中,评估了肝纤维化的进展、逆转和功能特征。
单细胞 RNA 测序数据集的分析表明,在人类肝硬化中 CtsD 在巨噬细胞和肝细胞中表达。在新型髓样 CtsD(CtsD)和肝细胞 CtsD 敲除小鼠中,评估了肝纤维化的进展、逆转和功能特征。巨噬细胞而非肝细胞中的 CtsD 缺失导致肝纤维化增强。在纤维化的 CtsD 肝脏中,炎症和基质组蛋白组学特征均得到富集。此外,CtsD 肝脏巨噬细胞显示出功能、表型和分泌组的变化,导致体外胶原 I 的蛋白水解加工缺陷和体内纤维化消退过程中胶原重塑受损。最后,在肝硬化人类肝脏的单核吞噬细胞中,CtsD 表达的单核吞噬细胞富含溶酶体和 ECM 降解信号通路。
我们的工作首次描述了 CtsD 驱动的溶酶体活性作为纤维化消退过程中修复性巨噬细胞功能的中心枢纽,并为探索其降解组景观以提供药物开发信息开辟了新途径。